Physician profile
Amanda Dimech
NPI 1194437970
$1,993.80
in general payments reported to CMS, 2019-2025
12 companies · $230 in 2025
The $230 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,215 · 2024: $549 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,937 · Education: $56.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,936.81 |
| Education | $56.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $766.79 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $715.11 | 2023-2024 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $185.02 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $56.99 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.24 | 2023 | Takhzyro, Cuvitru |
| Genentech USA, INC. | $49.88 | 2023-2024 | Xolair |
| Grifols USA, LLC | $41.90 | 2023-2024 | Xembify |
| Novartis Pharmaceuticals Corporation | $33.79 | 2024 | |
| Octapharma USA, INC. | $31.38 | 2023 | Cutaquig |
| Mylan Specialty L.P. | $25.57 | 2023 | Yupelri |
| Hikma Pharmaceuticals USA | $22.14 | 2023 | Ryaltris |
| Amgen INC. | $12.99 | 2023 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Dimech listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.